Chemomab Therapeutics (CMMB) Price & Analysis

Compare

271 Followers

CMMB Stock Chart & Stats

Day’s Range― - ―

52-Week Range$3.05 - $9.96

Previous CloseN/A

Volume58.22K

Average Volume (3M)81.83K

Market Cap

$16.24M

Enterprise Value$17.37M

Total Cash (Recent Filing)$10.56M

Total Debt (Recent Filing)$292.00K

Price to Earnings (P/E)―

Beta1.17

Next Earnings

Nov 07, 2025

EPS Estimate

-0.02

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.02

Shares Outstanding5,191,075

10 Day Avg. Volume182,292

30 Day Avg. Volume81,829

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap1.07

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-645.71

Enterprise Value/Ebitda-1.23

Forecast

1Y Price Target

$29.67

Price Target Upside857.10% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Clinical Trial DesignFavorable regulatory feedback enables a streamlined pivotal program, positioning Chemomab for a more efficient and lower-cost pivotal study.

Drug MechanismChemomab's CM-101 is differentiated from other drugs due to its dual-acting mechanism on inflammation and fibrosis.

Regulatory ApprovalChemomab has received positive feedback from the FDA, which supports the advancement of Nebokitug into Phase 3 for primary sclerosing cholangitis.

Bears Say

Enrollment ComplicationsAvoiding a biopsy endpoint was a key objective of Chemomab's regulatory interactions. Biopsy endpoints complicate enrollment and add considerable additional cost.

Study ComplexityThe lack of a required confirmatory keeps timelines on track and reduces the overall cost.

Chemomab Therapeutics News

Chemomab Therapeutics price target raised to $25 from $10 at Oppenheimer

Oppenheimer raised the firm’s price target on Chemomab Therapeutics (CMMB) to $25 from $10 and keeps an Outperform...

8d ago

CMMB

Chemomab Therapeutics Ltd – ADR trading halted, news pending

19:50 EDT Chemomab Therapeutics (CMMB) Ltd – ADR trading halted, news pending Published first on TheFly – the...

9d ago

CMMB

Upcoming Stock Splits This Week (August 25 to August 29) – Stay Invested

These are the upcoming stock splits for the week of August 25 to August 29, based on TipRanks’ Stock...

11d ago

Chemomab Therapeutics reports Q2 EPS 0.4c vs 0.013c last year

“In the second quarter of 2025 Chemomab continued to lay the groundwork for the nebokitug Phase 3 program...

21d ago

CMMB

Chemomab Therapeutics Announces ADS Ratio Change Effective August 26, 2025

Chemomab Therapeutics ( ($CMMB) ) has shared an update. Chemomab Therapeutics Ltd. announced a change in the ratio...

13d ago

CMMB

Chemomab Therapeutics: Advancing CM-101 with Strategic Financial Optimizations and FDA Support

Maxim Group analyst Michael Okunewitch has maintained their bullish stance on CMMB stock, giving a Buy rating today....

20d ago

CMMB

Chemomab Therapeutics Reports Q2 2025 Financial Results

Chemomab Therapeutics ( ($CMMB) ) has shared an announcement. On August 14, 2025, Chemomab Therapeutics Ltd. announced its...

21d ago

CMMB

Chemomab Therapeutics management to meet with Maxim

Meeting to be held on August 7-8 hosted by Maxim. Published first on TheFly – the ultimate source...

1M ago

CMMB

Chemomab Therapeutics Enters Sales Agreement with LifeSci Capital

The latest announcement is out from Chemomab Therapeutics ( ($CMMB) ). On July 25, 2025, Chemomab Therapeutics Ltd....

1M ago

CMMB

Chemomab Therapeutics Announces Key Decisions from Annual Shareholders Meeting

Chemomab Therapeutics ( ($CMMB) ) has provided an announcement. On July 1, 2025, Chemomab Therapeutics held its annual...

2M ago

CMMB

Chemomab Therapeutics announces data from Phase 2 SPRING trial of nebokitug

Chemomab Therapeutics (CMMB) announced that data from the company’s Phase 2 SPRING trial of nebokitug in patients with...

2M ago

CMMB

Chemomab obtained feedback from two recent FDA meetings on nebokitug

Chemomab Therapeutics (CMMB) reported that it has obtained confirmation from the FDA on two significant development milestones as...

3M ago

CMMB

Chemomab announces nebokitug awarded new patent protection in China, Russia

Chemomab Therapeutics (CMMB) announced that its lead product nebokitug has been awarded new patent protections in China and...

3M ago

CMMB

Chemomab Therapeutics Announces Annual General Meeting for July 2025

Chemomab Therapeutics ( ($CMMB) ) just unveiled an announcement. On May 27, 2025, Chemomab Therapeutics announced its upcoming...

3M ago

CMMB

CMMB FAQ

What was Chemomab Therapeutics’s price range in the past 12 months?

Chemomab Therapeutics lowest stock price was $3.05 and its highest was $9.96 in the past 12 months.

What is Chemomab Therapeutics’s market cap?

Chemomab Therapeutics’s market cap is $16.24M.

When is Chemomab Therapeutics’s upcoming earnings report date?

Chemomab Therapeutics’s upcoming earnings report date is Nov 07, 2025 which is in 64 days.

How were Chemomab Therapeutics’s earnings last quarter?

Chemomab Therapeutics released its earnings results on Aug 14, 2025. The company reported -$0.016 earnings per share for the quarter, beating the consensus estimate of -$0.04 by $0.024.

Is Chemomab Therapeutics overvalued?

According to Wall Street analysts Chemomab Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Chemomab Therapeutics pay dividends?

Chemomab Therapeutics does not currently pay dividends.

What is Chemomab Therapeutics’s EPS estimate?

Chemomab Therapeutics’s EPS estimate is -0.02.

How many shares outstanding does Chemomab Therapeutics have?

Chemomab Therapeutics has 5,191,075 shares outstanding.

What happened to Chemomab Therapeutics’s price movement after its last earnings report?

Chemomab Therapeutics reported an EPS of -$0.016 in its last earnings report, beating expectations of -$0.04. Following the earnings report the stock price went down -6.266%.

Which hedge fund is a major shareholder of Chemomab Therapeutics?

Currently, no hedge funds are holding shares in CMMB

Chemomab Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-120.76%

Trailing 12-Months

Asset Growth

-23.48%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Chemomab Therapeutics

Chemomab Therapeutics (CMMB) is a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for the treatment of inflammatory and fibrotic diseases. The company's core product is CM-101, a monoclonal antibody designed to address key pathways involved in fibrosis and inflammation, offering potential treatments for conditions such as primary sclerosing cholangitis (PSC), systemic sclerosis, and liver fibrosis.

Chemomab Therapeutics (CMMB) Earnings & Revenues

Historic Earnings Reports

CMMB Stock 12 Month Forecast

Average Price Target

$29.67

▲(857.10% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","10":"$10","19":"$19","28":"$28","37":"$37"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":36,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$36.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":29.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$29.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$25.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,10,19,28,37],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Nov<br/>2024","9":"Mar<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.1,6.553846153846154,9.007692307692306,11.46153846153846,13.915384615384614,16.369230769230768,18.82307692307692,21.276923076923076,23.730769230769226,26.184615384615384,28.638461538461534,31.092307692307692,33.54615384615384,{"y":36,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.1,6.066923076923077,8.033846153846154,10.00076923076923,11.967692307692307,13.934615384615384,15.901538461538461,17.86846153846154,19.835384615384616,21.802307692307693,23.769230769230766,25.736153846153847,27.70307692307692,{"y":29.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.1,5.707692307692307,7.315384615384614,8.923076923076923,10.53076923076923,12.138461538461538,13.746153846153845,15.353846153846153,16.96153846153846,18.569230769230767,20.176923076923075,21.784615384615385,23.39230769230769,{"y":25,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.12,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.9,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.28,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.86,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.66,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.52,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.24,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.16,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.72,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.48,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.4,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.1,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >